{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1460","value":"0.2883"}]}],"title":"Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0827","value":"0.1105"}]}],"title":"PF-05199265"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Fluctuation coefficient between trough and peak plasma concentration was determined as Cmax-Ctrough divided by Cavg, where Cmax was the maximum observed concentration within the dosing interval, Ctrough was the observed concentration prior to dose administration and Cavg was averaged plasma concentration at steady state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"}],"paramType":"MEAN","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","title":"Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265","type":"SECONDARY","unitOfMeasure":"Fluctuation coefficient"}